Dual action immunotherapy in CAR-T cells improves control of B-cell acute lymphoblastic leukemia progression

B-cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children, accounting for around 85% of pediatric leukemia cases. According to REDECAN, more than 400 new cases are estimated to be diagnosed in Spain in 2025, and about 20% of patients are not expected to survive beyond five years.

Leave A Comment

Your email address will not be published. Required fields are marked *